Hyperion DeFi (HYPD) vs Zhengye Biotechnology (ZYBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Zhengye Biotechnology (ZYBT) has outperformed Hyperion DeFi (HYPD) over the past year, losing 62.7% versus a loss of 62.9%. Zhengye Biotechnology is the larger company by market cap ($54.5 million vs $51.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HYPD | ZYBT |
|---|---|---|
| Share price | $3.37 | $1.15 |
| Market cap | $51.16M | $54.50M |
| 1-day change | -6.27% | -0.87% |
| YTD return | -5.48% | -0.01% |
| 1-year return | -62.86% | -62.67% |
| 5-year return | -99.21% | — |
| EPS (TTM) | $-6.46 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.50 | $8.01 |
| 52-week low | $2.34 | $0.616 |
| Distance from 52-week high | -64.58% | -85.64% |
| Analyst consensus | none | — |
| Avg. price target upside | +192.12% | — |
| Average volume | 445.34K | 5.10M |
| Shares outstanding | 15.20M | 47.39M |
| Employees | 9 | 269 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Hyperion DeFi
HYPD stock →Hyperion DeFi, Inc., a DeFi company, engages in building on Hyperliquid. It operates through two segments: Ophthalmic Technology and Digital Assets.
Healthcare · Biotechnology · 9 employees
About Zhengye Biotechnology
ZYBT stock →Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.
Healthcare · Drug Manufacturers - Specialty & Generic · 269 employees
HYPD vs ZYBT FAQ
Which is bigger, Hyperion DeFi or Zhengye Biotechnology?
Zhengye Biotechnology (ZYBT) is larger, with a market capitalization of $54.50M compared with $51.16M for Hyperion DeFi (HYPD).
Which stock has performed better over the past year, HYPD or ZYBT?
ZYBT returned -62.67% over the past 12 months, compared with -62.86% for HYPD (price return, excluding dividends). Past performance does not predict future results.
Are Hyperion DeFi and Zhengye Biotechnology in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for Hyperion DeFi and Drug Manufacturers - Specialty & Generic for Zhengye Biotechnology.